| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| References | |
|---|---|
| Additional Infomation |
Cassoprete belongs to the piperidine class of drugs. Cassoprete is a centrally acting neurokinin 1 (NK1) receptor antagonist with antidepressant and antiemetic effects. Cassoprete competitively binds to and blocks the activity of the NK1 receptor, thereby inhibiting the binding of the endogenous tachykinin neuropeptide P (SP) to the NK1 receptor, which may produce an antiemetic effect. SP is present in neurons innervating vagal afferent fibers of the nucleus tractus solitarius and the post-traumatic zone (containing the chemoreceptor trigger zone (CTZ)) in the brainstem; SP levels may increase after chemotherapy. The NK1 receptor is a G protein-coupled receptor coupled to the inositol phosphate signaling pathway and is present in the nucleus tractus solitarius and the post-traumatic zone. See also: Cassoprete mesylate (active ingredient).
Drug Indication Research its use/efficacy in the treatment of urinary incontinence and its adverse reactions (chemotherapy). |
| Molecular Formula |
C30H35F7N4O2
|
|---|---|
| Molecular Weight |
616.61
|
| Exact Mass |
616.265
|
| CAS # |
414910-27-3
|
| Related CAS # |
(R)-Casopitant;414910-26-2;Casopitant mesylate;414910-30-8
|
| PubChem CID |
9917021
|
| Appearance |
Typically exists as solids at room temperature
|
| LogP |
6.468
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
43
|
| Complexity |
949
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC1=C(C=CC(=C1)F)C2CC(CCN2C(=O)N(C)C(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C
|
| InChi Key |
XGGTZCKQRWXCHW-WMTVXVAQSA-N
|
| InChi Code |
InChI=1S/C30H35F7N4O2/c1-18-13-24(31)5-6-26(18)27-17-25(40-11-9-39(10-12-40)20(3)42)7-8-41(27)28(43)38(4)19(2)21-14-22(29(32,33)34)16-23(15-21)30(35,36)37/h5-6,13-16,19,25,27H,7-12,17H2,1-4H3/t19-,25+,27-/m1/s1
|
| Chemical Name |
(2R,4S)-4-(4-acetylpiperazin-1-yl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide
|
| Synonyms |
GW679769
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6218 mL | 8.1089 mL | 16.2177 mL | |
| 5 mM | 0.3244 mL | 1.6218 mL | 3.2435 mL | |
| 10 mM | 0.1622 mL | 0.8109 mL | 1.6218 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT00601172
Conditions:Nausea and Vomiting, Chemotherapy-InducedLink: https://clinicaltrials.gov/ct2/show/NCT00334646
Conditions:Nausea and Vomiting, Chemotherapy-InducedLink: https://clinicaltrials.gov/ct2/show/NCT00359177
Conditions:Vomiting
Title:Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant GW679769
Status:Completed
updateDate:2017-09-12
Ctid:NCT00404378
Link: https://clinicaltrials.gov/ct2/show/NCT00404378
Conditions:Nausea and Vomiting, Chemotherapy-InducedLink: https://clinicaltrials.gov/ct2/show/NCT00431236
Conditions:Nausea and Vomiting, Chemotherapy-InducedLink: https://clinicaltrials.gov/ct2/show/NCT00650871
Conditions:Sleep Initiation and Maintenance DisordersLink: https://clinicaltrials.gov/ct2/show/NCT00358813
Conditions:VomitingLink: https://clinicaltrials.gov/ct2/show/NCT00460707
Conditions:Nausea and Vomiting, Chemotherapy-InducedLink: https://clinicaltrials.gov/ct2/show/NCT00511823
Conditions:Nausea and Vomiting, Chemotherapy-InducedLink: https://clinicaltrials.gov/ct2/show/NCT00334152
Conditions:Nausea and Vomiting, Postoperative|Postoperative Nausea and VomitingLink: https://clinicaltrials.gov/ct2/show/NCT00358410
Conditions:Nonulcer DyspepsiaLink: https://clinicaltrials.gov/ct2/show/NCT00274690
Conditions:Postoperative Nausea and Vomiting|Nausea and Vomiting, PostoperativeLink: https://clinicaltrials.gov/ct2/show/NCT00321477
Conditions:Incontinence, Urinary and Urinary Bladder, Overactive|Overactive BladderLink: https://clinicaltrials.gov/ct2/show/NCT00413023
Conditions:Depressive Disorder, MajorLink: https://clinicaltrials.gov/ct2/show/NCT00326248
Conditions:Nausea and Vomiting, PostoperativeLink: https://clinicaltrials.gov/ct2/show/NCT00332319
Conditions:Incontinence, Urinary and Urinary Bladder, Overactive|Overactive BladderLink: https://clinicaltrials.gov/ct2/show/NCT00104403
Conditions:Nausea and Vomiting, Chemotherapy-Induced|Chemotherapy-Induced Nausea and VomitingLink: https://clinicaltrials.gov/ct2/show/NCT00280436
Conditions:Sleep Initiation and Maintenance Disorders|InsomniaLink: https://clinicaltrials.gov/ct2/show/NCT00264628
Conditions:Depressive Disorder|Depression|FibromyalgiaLink: https://clinicaltrials.gov/ct2/show/NCT00102492
Conditions:Depressive Disorder, Major|Major Depressive Disorder (MDD)Link: https://clinicaltrials.gov/ct2/show/NCT00354809
Conditions:Sleep Initiation and Maintenance Disorders|InsomniaLink: https://clinicaltrials.gov/ct2/show/NCT00280423
Conditions:Sleep Initiation and Maintenance Disorders|InsomniaLink: https://clinicaltrials.gov/ct2/show/NCT00169572
Conditions:Nausea and Vomiting|Chemotherapy-InducedLink: https://clinicaltrials.gov/ct2/show/NCT00332046
Conditions:Social Anxiety DisorderLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005856-42
Condition:Postoperative Nausea and Vomiting (PONV)Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005855-16
Condition:Postoperative Nausea and Vomiting (PONV)Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001010-41
Condition:FibromyalgiaLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004984-32
Condition:Major Depressive Disorder (MDD)Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000370-31
Condition:Post Operative Nausea and Vomiting (PONV)Post Discharge Nausea and Vomiting (PDNV)Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000369-37
Condition:Post Operative Nausea and Vomiting (PONV)Post Discharge Nausea and Vomiting (PDNV)Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001020-20
Condition:Chemotherapy Induced Nausea and Vomiting (CINV) 0 Moderately Emetogenic Chemotherapy (MEC)Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000371-34
Condition:Chemotherapy-Induced Nausea and Vomiting (CINV) - Highly Emetogenic Chemotherapy (HEC)Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
